Tempest to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tempest Therapeutics, Inc. (Nasdaq: TPST) has announced its participation in two upcoming investor conferences in September 2021. The company will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. ET and at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22 at 9:55 a.m. ET. Tempest is progressing its clinical-stage oncology programs, including TPST-1495 and TPST-1120, which target cancer treatment through innovative mechanisms. For more details, visit the Tempest investor website.

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in September:

• H.C. Wainwright 23rd Annual Global Investment Conference available on-demand Monday, September 13, 2021 at 7:00 a.m. ET
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday September 22, 2021 at 9:55 a.m. ET

To access the live or archived recording of the company presentations, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When will Tempest Therapeutics present at the H.C. Wainwright conference?

Tempest Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET.

What is the date of the Oppenheimer Fall Healthcare Summit for Tempest Therapeutics?

The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for September 22, 2021, at 9:55 a.m. ET.

What are TPST-1495 and TPST-1120?

TPST-1495 and TPST-1120 are novel clinical programs developed by Tempest Therapeutics as potential treatments for a variety of tumors.

How can I access Tempest Therapeutics' conference presentations?

You can access live or archived recordings of the presentations on Tempest's investor section of their website.

What mechanisms do Tempest Therapeutics' drugs target?

Tempest's drugs combine targeted and immune-mediated mechanisms for treating cancer.